NASDAQ:KPTI Karyopharm Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $16.32 +0.23 (+1.43 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$15.87Now: $16.32▼$16.4850-Day Range$14.14MA: $15.10▼$16.8652-Week Range$8.91Now: $16.32▼$29.61Volume1.50 million shsAverage Volume1.67 million shsMarket Capitalization$1.20 billionP/E RatioN/ADividend YieldN/ABeta1.18 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIOTM (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency (EMA). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.Read More Beat the Market (BTM) Rank™ 4.4 Analyst's Opinion Consensus RatingKaryopharm Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $33.22, Karyopharm Therapeutics has a forecasted upside of 103.6% from its current price of $16.32.Amount of Analyst CoverageKaryopharm Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Community Rank Outperform VotesKaryopharm Therapeutics has received 493 “outperform” votes. (Add your “outperform” vote.)Underperform VotesKaryopharm Therapeutics has received 322 “underperform” votes. (Add your “underperform” vote.)Community SentimentKaryopharm Therapeutics has received 60.49% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Karyopharm Therapeutics and other stocks. Vote “Outperform” if you believe KPTI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KPTI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldKaryopharm Therapeutics does not currently pay a dividend.Dividend GrowthKaryopharm Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Karyopharm Therapeutics insiders have sold 591.44% more of their company's stock than they have bought. Specifically, they have bought $109,050.00 in company stock and sold $754,014.00 in company stock.Percentage Held by InsidersOnly 11.63% of the stock of Karyopharm Therapeutics is held by insiders.Percentage Held by Institutions95.90% of the stock of Karyopharm Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Karyopharm Therapeutics are expected to grow in the coming year, from ($2.63) to ($1.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Karyopharm Therapeutics is -5.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Karyopharm Therapeutics is -5.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKaryopharm Therapeutics has a P/B Ratio of 20.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.81 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KPTI Previous Symbol CUSIPN/A CIK1503802 Webwww.karyopharm.com Phone617-658-0600Debt Debt-to-Equity Ratio0.88 Current Ratio6.29 Quick Ratio6.25Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$40.89 million Price / Sales29.33 Cash FlowN/A Price / Cash FlowN/A Book Value$0.79 per share Price / Book20.66Profitability EPS (Most Recent Fiscal Year)($3.22) Net Income$-199,590,000.00 Net Margins-228.44% Return on Equity-186.76% Return on Assets-54.54%Miscellaneous Employees332 Outstanding Shares73,478,000Market Cap$1.20 billion Next Earnings Date11/2/2020 (Estimated) OptionableOptionable $16.32 +0.23 (+1.43 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive KPTI News and Ratings via Email Sign-up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Karyopharm Therapeutics (NASDAQ:KPTI) Frequently Asked Questions How has Karyopharm Therapeutics' stock been impacted by COVID-19? Karyopharm Therapeutics' stock was trading at $21.24 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, KPTI stock has decreased by 23.2% and is now trading at $16.32. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Karyopharm Therapeutics? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Karyopharm Therapeutics. When is Karyopharm Therapeutics' next earnings date? Karyopharm Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020. View our earnings forecast for Karyopharm Therapeutics. How were Karyopharm Therapeutics' earnings last quarter? Karyopharm Therapeutics Inc (NASDAQ:KPTI) issued its earnings results on Tuesday, August, 4th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.57) by $0.06. The company had revenue of $33.51 million for the quarter, compared to analysts' expectations of $28.03 million. Karyopharm Therapeutics had a negative net margin of 228.44% and a negative return on equity of 186.76%. View Karyopharm Therapeutics' earnings history. What price target have analysts set for KPTI? 10 analysts have issued 12-month price objectives for Karyopharm Therapeutics' shares. Their forecasts range from $26.00 to $41.00. On average, they expect Karyopharm Therapeutics' stock price to reach $33.22 in the next year. This suggests a possible upside of 103.6% from the stock's current price. View analysts' price targets for Karyopharm Therapeutics. Who are some of Karyopharm Therapeutics' key competitors? Some companies that are related to Karyopharm Therapeutics include United Therapeutics (UTHR), Zai Lab (ZLAB), HUTCHISON CHINA/S (HCM), Arrowhead Pharmaceuticals (ARWR), Blueprint Medicines (BPMC), Legend Biotech (LEGN), Allakos (ALLK), Arena Pharmaceuticals (ARNA), FibroGen (FGEN), Evotec (EVTCY), ChemoCentryx (CCXI), Biohaven Pharmaceutical (BHVN), Amicus Therapeutics (FOLD), Turning Point Therapeutics (TPTX) and Nektar Therapeutics (NKTR). View all competitors. What other stocks do shareholders of Karyopharm Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Crispr Therapeutics (CRSP), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), Micron Technology (MU), AbbVie (ABBV), Bristol-Myers Squibb (BMY), InVitae (NVTA) and Sorrento Therapeutics (SRNE). Who are Karyopharm Therapeutics' key executives? Karyopharm Therapeutics' management team includes the following people: Dr. Michael G. Kauffman, Co-Founder, CEO & Director (Age 56)Dr. Sharon Shacham, Co-Founder, Pres, Chief Scientific Officer & Co-Chairman of Scientific Advisory Board (Age 49)Mr. Christopher Brett Primiano, Exec. VP, Chief Bus. Officer, Gen. Counsel & Sec. (Age 38)Dr. Mansoor Raza Mirza, Clinical Consultant, Member of Scientific Advisory Board & Director (Age 58)Mr. Michael P. Mason, Sr. VP, CFO & Treasurer (Age 44) What is Karyopharm Therapeutics' stock symbol? Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI." Who are Karyopharm Therapeutics' major shareholders? Karyopharm Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.85%), Frontier Capital Management Co. LLC (3.82%), Goldman Sachs Group Inc. (2.72%), Emerald Advisers LLC (1.70%), Emerald Mutual Fund Advisers Trust (1.42%) and Two Sigma Advisers LP (1.23%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Jatin Shah, John Demaree, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman, Ran Frenkel and Sharon Shacham. View institutional ownership trends for Karyopharm Therapeutics. Which institutional investors are selling Karyopharm Therapeutics stock? KPTI stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Atom Investors LP, Caption Management LLC, Sei Investments Co., Bank of New York Mellon Corp, Virtus ETF Advisers LLC, and Arizona State Retirement System. Company insiders that have sold Karyopharm Therapeutics company stock in the last year include Christopher Brett Primiano, Jatin Shah, Mansoor Raza Mirza, Michael Kauffman, Ran Frenkel, and Sharon Shacham. View insider buying and selling activity for Karyopharm Therapeutics. Which institutional investors are buying Karyopharm Therapeutics stock? KPTI stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Frontier Capital Management Co. LLC, Vanguard Group Inc., Balyasny Asset Management LLC, Emerald Advisers LLC, Two Sigma Advisers LP, Emerald Mutual Fund Advisers Trust, and Nuveen Asset Management LLC. View insider buying and selling activity for Karyopharm Therapeutics. How do I buy shares of Karyopharm Therapeutics? Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Karyopharm Therapeutics' stock price today? One share of KPTI stock can currently be purchased for approximately $16.32. How big of a company is Karyopharm Therapeutics? Karyopharm Therapeutics has a market capitalization of $1.20 billion and generates $40.89 million in revenue each year. The company earns $-199,590,000.00 in net income (profit) each year or ($3.22) on an earnings per share basis. Karyopharm Therapeutics employs 332 workers across the globe. What is Karyopharm Therapeutics' official website? The official website for Karyopharm Therapeutics is www.karyopharm.com. How can I contact Karyopharm Therapeutics? Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company can be reached via phone at 617-658-0600 or via email at [email protected] This page was last updated on 9/19/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
